Form 4: Jazz Pharmaceuticals Executive Receives Stock Grants

Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals, reports the acquisition of restricted stock units.

Summary

• Samantha Pearce, EVP, Chief Commercial Officer of Jazz Pharmaceuticals, reported transactions involving ordinary shares.
• On February 27, 2025, Pearce acquired 11,941 ordinary shares and 5,778 ordinary shares.
• These shares were granted as restricted stock units under the company's 2011 Equity Incentive Plan.
• Following these transactions, Pearce directly owns 43,131 ordinary shares.
• The 11,941 restricted stock units vest in equal annual installments over four years, starting March 5, 2025.
• The 5,778 restricted stock units will vest in full on June 30, 2026.

Sentiment

Score: 7

Explanation: The document reflects a neutral to slightly positive sentiment as it reports standard executive compensation practices, indicating confidence in the company's future.

Positives

• The grant of restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in the pharmaceutical industry, similar to companies like Amgen, Gilead Sciences, and Biogen.
• The vesting schedules are also standard, often ranging from three to five years to encourage long-term commitment.

Stakeholder Impact

• The stock grants align the executive's interests with those of the shareholders, potentially leading to better company performance.
• Employees may view the stock grants as a positive sign of the company's commitment to its leadership.

Key Dates